Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 864 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $15.20, for a total value of $13,132.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Gina Consylman also recently made the following trade(s):
- On Friday, August 18th, Gina Consylman sold 207 shares of Ironwood Pharmaceuticals stock. The shares were sold at an average price of $14.34, for a total value of $2,968.38.
Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) traded down $0.05 during trading on Wednesday, hitting $14.93. 661,100 shares of the stock traded hands, compared to its average volume of 1,302,958. Ironwood Pharmaceuticals, Inc. has a 52-week low of $13.43 and a 52-week high of $19.94. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.18) earnings per share. sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) CFO Gina Consylman Sells 864 Shares of Stock” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/11/15/ironwood-pharmaceuticals-inc-irwd-cfo-gina-consylman-sells-864-shares-of-stock.html.
Several equities analysts recently commented on IRWD shares. Wood & Company downgraded Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Mizuho reissued a “buy” rating and set a $20.00 target price (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. Wells Fargo & Company set a $19.00 target price on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, July 22nd. BidaskClub cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Finally, Cowen and Company set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 21st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $18.29.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. Janus Henderson Group PLC bought a new position in Ironwood Pharmaceuticals in the second quarter valued at $150,460,000. EcoR1 Capital LLC boosted its position in Ironwood Pharmaceuticals by 29.2% during the second quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock valued at $70,869,000 after buying an additional 848,120 shares during the period. Pictet Asset Management Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 37.5% during the third quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock worth $41,357,000 after purchasing an additional 715,147 shares during the period. Penn Capital Management Co. Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 258.4% during the second quarter. Penn Capital Management Co. Inc. now owns 855,314 shares of the biotechnology company’s stock worth $16,261,000 after purchasing an additional 616,686 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 5.7% during the first quarter. Vanguard Group Inc. now owns 10,505,461 shares of the biotechnology company’s stock worth $179,223,000 after purchasing an additional 562,179 shares during the period. 98.83% of the stock is currently owned by institutional investors and hedge funds.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.